JP7680351B2 - ゲノムを調節するための方法及び組成物 - Google Patents

ゲノムを調節するための方法及び組成物 Download PDF

Info

Publication number
JP7680351B2
JP7680351B2 JP2021511605A JP2021511605A JP7680351B2 JP 7680351 B2 JP7680351 B2 JP 7680351B2 JP 2021511605 A JP2021511605 A JP 2021511605A JP 2021511605 A JP2021511605 A JP 2021511605A JP 7680351 B2 JP7680351 B2 JP 7680351B2
Authority
JP
Japan
Prior art keywords
sequence
rna
dna
polypeptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021511605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534798A5 (enExample
JP2021534798A (ja
Inventor
ジェイコブ ローゼンブラム ルーベンス，
マルツァーン， ジェフリー エー． ヴォン
ロバート ジェイムズ シトリク，
バレット イーサン スタインバーグ，
ドンフイ リー，
ウィリアム エドワード サロモン，
Original Assignee
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー filed Critical フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー
Publication of JP2021534798A publication Critical patent/JP2021534798A/ja
Publication of JP2021534798A5 publication Critical patent/JP2021534798A5/ja
Priority to JP2025011363A priority Critical patent/JP2025063317A/ja
Application granted granted Critical
Publication of JP7680351B2 publication Critical patent/JP7680351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021511605A 2018-08-28 2019-08-28 ゲノムを調節するための方法及び組成物 Active JP7680351B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025011363A JP2025063317A (ja) 2018-08-28 2025-01-27 ゲノムを調節するための方法及び組成物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862723886P 2018-08-28 2018-08-28
US62/723,886 2018-08-28
US201862725778P 2018-08-31 2018-08-31
US62/725,778 2018-08-31
US201962850883P 2019-05-21 2019-05-21
US62/850,883 2019-05-21
US201962864924P 2019-06-21 2019-06-21
US62/864,924 2019-06-21
PCT/US2019/048607 WO2020047124A1 (en) 2018-08-28 2019-08-28 Methods and compositions for modulating a genome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025011363A Division JP2025063317A (ja) 2018-08-28 2025-01-27 ゲノムを調節するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2021534798A JP2021534798A (ja) 2021-12-16
JP2021534798A5 JP2021534798A5 (enExample) 2022-09-06
JP7680351B2 true JP7680351B2 (ja) 2025-05-20

Family

ID=67997683

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511605A Active JP7680351B2 (ja) 2018-08-28 2019-08-28 ゲノムを調節するための方法及び組成物
JP2025011363A Pending JP2025063317A (ja) 2018-08-28 2025-01-27 ゲノムを調節するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025011363A Pending JP2025063317A (ja) 2018-08-28 2025-01-27 ゲノムを調節するための方法及び組成物

Country Status (10)

Country Link
US (3) US12031129B2 (enExample)
EP (1) EP3844272A1 (enExample)
JP (2) JP7680351B2 (enExample)
KR (1) KR20210049859A (enExample)
CN (1) CN113286880A (enExample)
AU (2) AU2019327449B2 (enExample)
BR (1) BR112021003380A2 (enExample)
CA (1) CA3109953A1 (enExample)
IL (1) IL280947A (enExample)
WO (1) WO2020047124A1 (enExample)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
MX2019015505A (es) 2017-06-30 2020-07-28 Inscripta Inc Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados.
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
AU2019327449B2 (en) 2018-08-28 2026-04-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3953477A4 (en) 2019-06-06 2022-06-22 Inscripta, Inc. HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING
US20220298495A1 (en) * 2019-06-12 2022-09-22 Emendobio Inc. Novel genome editing tool
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2021046243A2 (en) * 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US20230040216A1 (en) * 2019-11-19 2023-02-09 The Broad Institute, Inc. Retrotransposons and use thereof
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
WO2021126886A1 (en) 2019-12-18 2021-06-24 Inscripta, Inc. Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
BR112022017715A2 (pt) * 2020-03-04 2022-11-16 Flagship Pioneering Innovations Vi Llc Métodos e composições para modular um genoma
IL296095A (en) 2020-03-04 2022-11-01 Flagship Pioneering Innovations Vi Llc Improved methods and compositions for genome modulation
AU2021232005A1 (en) * 2020-03-04 2022-09-29 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
BR112022017735A2 (pt) * 2020-03-05 2022-11-29 Flagship Pioneering Innovations Vi Llc Métodos e composições de supressão de defesa de hospedeiro para modular um genoma
WO2021188840A1 (en) * 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
CN115427566A (zh) * 2020-04-08 2022-12-02 阿斯利康(瑞典)有限公司 用于改善的位点特异性修饰的组合物和方法
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2021248102A1 (en) * 2020-06-05 2021-12-09 Flagship Pioneering Innovations Vi, Llc Template guide rna molecules
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
EP4214314A4 (en) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
KR20230091894A (ko) 2020-10-21 2023-06-23 메사추세츠 인스티튜트 오브 테크놀로지 부위 특이적 표적화 요소를 통한 프로그램 가능한 첨가(paste)를 사용하는 부위 특이적 유전 공학을 위한 시스템, 방법, 및 조성물
WO2022125329A1 (en) * 2020-12-07 2022-06-16 Inscripta, Inc. gRNA STABILIZATION IN NUCLEIC ACID-GUIDED NICKASE EDITING
CA3204158A1 (en) 2021-01-04 2022-07-07 Juhan Kim Mad nucleases
CN116745428A (zh) * 2021-01-14 2023-09-12 加利福尼亚大学董事会 位点特异性基因修饰
CN112708636A (zh) * 2021-01-22 2021-04-27 彭双红 基因转录框架、载体系统、基因组序列编辑方法及应用
US20240132916A1 (en) * 2021-02-09 2024-04-25 The Broad Institute, Inc. Nuclease-guided non-ltr retrotransposons and uses thereof
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
WO2022183210A1 (en) * 2021-02-26 2022-09-01 Flagship Pioneering Innovations Vi, Llc Tissue-specific methods and compositions for modulating a genome
AU2022240747A1 (en) * 2021-03-19 2023-10-05 Flagship Pioneering Innovations Vi, Llc Ltr transposon compositions and methods
AR125216A1 (es) 2021-03-26 2023-06-28 Flagship Pioneering Innovations Vii Llc Producción de polirribonucleótidos circulares en un sistema eucariota
US20250188505A1 (en) 2021-03-26 2025-06-12 Flagship Pioneering Innovations Vii, Llc Production of circular polyribonucleotides in a prokaryotic system
TW202300650A (zh) 2021-03-26 2023-01-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 真核系統中環狀多核糖核苷酸的產生
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
AU2022315304A1 (en) 2021-07-23 2024-02-08 Flagship Pioneering Innovations Vii, Llc Compositions for fungal control and related methods
CA3231712A1 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Pah-modulating compositions and methods
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
CN118119704A (zh) * 2021-09-08 2024-05-31 宏基因组学公司 用于转座货物核苷酸序列的系统和方法
KR20240051994A (ko) * 2021-09-08 2024-04-22 메타지노미, 인크. 레트로트랜스포존 및 이의 기능적 단편을 포함하는 시스템, 조성물, 및 방법
AR127073A1 (es) 2021-09-17 2023-12-13 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
EP4419706A1 (en) 2021-10-18 2024-08-28 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
WO2023069972A1 (en) * 2021-10-19 2023-04-27 Massachusetts Institute Of Technology Genomic editing with site-specific retrotransposons
EP4426828A1 (en) 2021-11-01 2024-09-11 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
EP4444362A4 (en) 2021-12-10 2026-04-01 Flagship Pioneering Innovations Vi Llc CFTR COMPOSITIONS AND MODULATION METHODS
US20250057980A1 (en) 2021-12-22 2025-02-20 Tome Biosciences, Inc. Co-Delivery of a Gene Editor Construct and a Donor Template
EP4453201A1 (en) 2021-12-22 2024-10-30 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
WO2023215727A2 (en) * 2022-05-02 2023-11-09 The Regents Of The University Of California Multicomponent systems for site-specific genome modifications
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
KR20250019772A (ko) 2022-05-25 2025-02-11 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 종양 억제인자 및 발암유전자를 조절하기 위한 조성물 및 방법
AU2023275550A1 (en) 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
CN119563038A (zh) 2022-05-25 2025-03-04 旗舰创业创新七公司 用于调节免疫应答的组合物和方法
EP4531879A1 (en) 2022-05-25 2025-04-09 Flagship Pioneering Innovations VI, LLC Compositions of secretory and/or catalytic cells and methods using the same
AU2023277636A1 (en) 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
EP4650780A3 (en) 2022-05-25 2026-01-21 Flagship Pioneering Innovations VII, LLC Compositions and methods for modulating circulating factors
JP2025525569A (ja) 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion
WO2024086586A2 (en) * 2022-10-18 2024-04-25 Flagship Pioneering Innovations Vi, Llc Improved gene editing systems utilizing trans recruiting components
EP4612296A1 (en) 2022-10-31 2025-09-10 Flagship Pioneering Innovations VI, LLC Compositions and methods for purifying polyribonucleotides
WO2024102799A1 (en) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
JP2026500188A (ja) * 2022-12-09 2026-01-06 メタゲノミ，インク． レトロトランスポゾン組成物および使用方法
WO2024131786A1 (zh) * 2022-12-19 2024-06-27 北京干细胞与再生医学研究院 一种在基因组插入大片段dna的系统
WO2024138194A1 (en) 2022-12-22 2024-06-27 Tome Biosciences, Inc. Platforms, compositions, and methods for in vivo programmable gene insertion
CN120958034A (zh) 2023-02-23 2025-11-14 微肽技术有限公司 用于产生和纯化肽的方法和组合物
EP4680276A1 (en) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
EP4680750A1 (en) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Compositions comprising polyribonucleotides and uses thereof
JP2026514069A (ja) * 2023-04-11 2026-05-01 ベイジン・アストラジェノミクス・テクノロジー・カンパニー，リミテッド 非ｌｔｒレトロトランスポゾンシステム及びその使用
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
WO2024220741A1 (en) 2023-04-19 2024-10-24 Flagship Pioneering Innovations Vii, Llc Compositions and methods for the production of libraries
WO2024234006A1 (en) 2023-05-11 2024-11-14 Tome Biosciences, Inc. Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
WO2025006419A1 (en) 2023-06-26 2025-01-02 Flagship Pioneering Innovations Vii, Llc Engineered plasmodia and related methods
CN121358858A (zh) * 2023-07-10 2026-01-16 北京干细胞与再生医学研究院 工程化的哺乳动物基因写入系统
CN121712890A (zh) * 2023-08-16 2026-03-20 基础科学研究院 使用具有单链断裂活性的CRISPR/Cas系统和PARP抑制剂的细胞死亡方法
EP4771154A2 (en) 2023-09-01 2026-07-08 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025050069A1 (en) 2023-09-01 2025-03-06 Tome Biosciences, Inc. Programmable gene insertion using engineered integration enzymes
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
AU2024361969A1 (en) * 2023-10-16 2026-04-23 The University Of Tokyo R2 retrotransposons for gene writing
WO2025128545A1 (en) * 2023-12-11 2025-06-19 Aera Therapeutics, Inc. Engineered mobile genetic element systems
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025132815A1 (en) 2023-12-20 2025-06-26 Novozymes A/S Novel cas nucleases and polynucleotides encoding the same
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025217194A1 (en) * 2024-04-09 2025-10-16 Typewriter Therapeutics, Inc. Repeat dosing of retrotransposons
WO2025224182A2 (en) 2024-04-23 2025-10-30 Basecamp Research Ltd Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
WO2026062521A2 (en) 2024-09-18 2026-03-26 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Methods and compounds for promoting survival of photoreceptors
WO2026132030A1 (en) 2024-12-19 2026-06-25 Novozymes A/S Cas nucleases and polynucleotides encoding the same
WO2026148005A1 (en) 2025-01-03 2026-07-09 Sail Biomedicines, Inc. Compositions and methods for purifying polyribonucleotides

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002291473A (ja) 2001-04-02 2002-10-08 New Industry Research Organization レトロトランスポゾン、プロモーター活性を有するｄｎａ断片、及びその利用
WO2003064644A1 (fr) 2002-01-31 2003-08-07 Dnavec Research Inc. Methode de retroposition de sequences line
JP2007515941A (ja) 2003-05-28 2007-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティ 合成された哺乳動物のレトロトランスポゾン遺伝子
WO2008072540A1 (ja) 2006-12-13 2008-06-19 National University Corporation Nagoya University Ｔｏｌ１因子のトランスポザーゼ及びそれを用いたＤＮＡ導入システム
JP2013511978A (ja) 2009-11-27 2013-04-11 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー キメラエンドヌクレアーゼおよびその使用
WO2017137768A1 (en) 2016-02-11 2017-08-17 Horizon Discovery Limited Replicative transposon system

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030121063A1 (en) 1995-11-16 2003-06-26 The Trustees Of The University Of Pennsylvania Compositions and methods of use of mammalian retrotransposons
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
CN1342758A (zh) * 2000-09-12 2002-04-03 上海博德基因开发有限公司 一种新的多肽——逆转录酶9.24和编码这种多肽的多核苷酸
US20070037759A1 (en) 2003-02-07 2007-02-15 Administrators Of The Tulane Educational Fund, The Mammalian retrotransposable elements
US20080104723A1 (en) * 2003-11-21 2008-05-01 Osaka Industrial Promojtion Organization C/O Mydom Development of Mammalian Genome Modification Technique Using Retrotransposon
MX2007014139A (es) * 2005-05-14 2008-10-09 Univ Fudan Piggybac como una herramienta para manipulacion genetica y analisis en vertebrados.
WO2007130543A2 (en) 2006-05-04 2007-11-15 Abmaxis Inc. Method for producing stable mammalian cell lines producing high levels of recombinant proteins
EP2055784A1 (en) 2007-10-31 2009-05-06 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Controlled activation of non-LTR retrotransposons in mammals
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
KR101911969B1 (ko) * 2011-02-23 2018-10-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Ｄｎａ 합성을 위한 주형 스위칭의 용도
US20140113375A1 (en) 2012-10-21 2014-04-24 Lixin Liu Transient Expression And Reverse Transcription Aided Genome Alteration System
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
ES2749624T3 (es) 2013-03-14 2020-03-23 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
DK3456831T3 (da) * 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
WO2016028843A2 (en) 2014-08-19 2016-02-25 President And Fellows Of Harvard College Rna-guided systems for probing and mapping of nucleic acids
WO2016036754A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification
WO2016065364A1 (en) 2014-10-24 2016-04-28 Life Technologies Corporation Compositions and methods for enhancing homologous recombination
EP3221457B1 (en) * 2014-11-21 2019-03-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
WO2016205728A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
WO2017059241A1 (en) 2015-10-02 2017-04-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral protein delivery system for rna-guided genome editing
WO2017123609A1 (en) 2016-01-12 2017-07-20 The Regents Of The University Of California Compositions and methods for enhanced genome editing
US20170275665A1 (en) 2016-02-24 2017-09-28 Board Of Regents, The University Of Texas System Direct crispr spacer acquisition from rna by a reverse-transcriptase-cas1 fusion protein
US11447768B2 (en) 2016-03-01 2022-09-20 University Of Florida Research Foundation, Incorporated Molecular cell diary system
ES3030658T3 (en) * 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
WO2017173004A1 (en) * 2016-03-30 2017-10-05 Mikuni Takayasu A method for in vivo precise genome editing
WO2017180711A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Grna fusion molecules, gene editing systems, and methods of use thereof
KR102370675B1 (ko) 2016-04-29 2022-03-04 바스프 플랜트 사이언스 컴퍼니 게엠베하 표적 핵산의 변형을 위한 개선된 방법
WO2017197238A1 (en) 2016-05-12 2017-11-16 President And Fellows Of Harvard College Aav split cas9 genome editing and transcriptional regulation
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
WO2018045321A1 (en) 2016-09-02 2018-03-08 North Carolina State University Methods and compositions for modification of plastid genomes
EP4431607A3 (en) 2016-09-09 2024-12-11 The Board of Trustees of the Leland Stanford Junior University High-throughput precision genome editing
US20190330620A1 (en) 2016-10-14 2019-10-31 Emendobio Inc. Rna compositions for genome editing
WO2018089860A1 (en) 2016-11-11 2018-05-17 2D Genomics Inc. Methods for processing nucleic acid samples
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
CA3063733A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Base editors with improved precision and specificity
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME
JP2021530212A (ja) 2018-07-13 2021-11-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California レトロトランスポゾンベースの送達媒体及びその使用方法
AU2019327449B2 (en) 2018-08-28 2026-04-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
CN117925571A (zh) 2018-10-19 2024-04-26 德克萨斯州大学系统董事会 工程化长散在元件（line）转座子及其使用方法
US12410429B2 (en) 2019-03-14 2025-09-09 Cornell University Compositions and methods for gene targeting using CRISPR-Cas and transposons
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US20220298495A1 (en) 2019-06-12 2022-09-22 Emendobio Inc. Novel genome editing tool
CA3147875A1 (en) 2019-07-19 2021-01-28 Flagship Pioneering Innovations Vi, Llc Recombinase compositions and methods of use
WO2021080922A1 (en) 2019-10-21 2021-04-29 The Trustees Of Columbia University In The City Of New York Methods of performing rna templated genome editing
EP4061940A4 (en) 2019-11-22 2024-10-23 Flagship Pioneering Innovations VI, LLC RECOMBINASE COMPOSITIONS AND METHODS OF USE
IL296095A (en) 2020-03-04 2022-11-01 Flagship Pioneering Innovations Vi Llc Improved methods and compositions for genome modulation
BR112022017715A2 (pt) 2020-03-04 2022-11-16 Flagship Pioneering Innovations Vi Llc Métodos e composições para modular um genoma
AU2021232005A1 (en) 2020-03-04 2022-09-29 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
US20230348939A1 (en) 2020-03-04 2023-11-02 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
BR112022017735A2 (pt) 2020-03-05 2022-11-29 Flagship Pioneering Innovations Vi Llc Métodos e composições de supressão de defesa de hospedeiro para modular um genoma
WO2021248102A1 (en) 2020-06-05 2021-12-09 Flagship Pioneering Innovations Vi, Llc Template guide rna molecules
WO2022183210A1 (en) 2021-02-26 2022-09-01 Flagship Pioneering Innovations Vi, Llc Tissue-specific methods and compositions for modulating a genome
AU2022240747A1 (en) 2021-03-19 2023-10-05 Flagship Pioneering Innovations Vi, Llc Ltr transposon compositions and methods
EP4347859A4 (en) 2021-05-26 2025-07-02 Flagship Pioneering Innovations Vi Llc INTEGRASE COMPOSITIONS AND METHODS
WO2023039447A2 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Serpina-modulating compositions and methods
CA3231712A1 (en) 2021-09-08 2023-03-16 Flagship Pioneering Innovations Vi, Llc Pah-modulating compositions and methods
KR20260037664A (ko) 2021-09-08 2026-03-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 게놈을 조절하기 위한 방법 및 조성물
MX2024002930A (es) 2021-09-08 2024-05-29 Flagship Pioneering Innovations Vi Llc Metodos y composiciones para modular un genoma.
EP4399307A4 (en) 2021-09-08 2026-01-21 Flagship Pioneering Innovations Vi Llc HBB COMPOSITIONS AND MODULATION METHODS
EP4444362A4 (en) 2021-12-10 2026-04-01 Flagship Pioneering Innovations Vi Llc CFTR COMPOSITIONS AND MODULATION METHODS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002291473A (ja) 2001-04-02 2002-10-08 New Industry Research Organization レトロトランスポゾン、プロモーター活性を有するｄｎａ断片、及びその利用
WO2003064644A1 (fr) 2002-01-31 2003-08-07 Dnavec Research Inc. Methode de retroposition de sequences line
JP2007515941A (ja) 2003-05-28 2007-06-21 ザ・ジョンズ・ホプキンス・ユニバーシティ 合成された哺乳動物のレトロトランスポゾン遺伝子
WO2008072540A1 (ja) 2006-12-13 2008-06-19 National University Corporation Nagoya University Ｔｏｌ１因子のトランスポザーゼ及びそれを用いたＤＮＡ導入システム
JP2013511978A (ja) 2009-11-27 2013-04-11 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー キメラエンドヌクレアーゼおよびその使用
WO2017137768A1 (en) 2016-02-11 2017-08-17 Horizon Discovery Limited Replicative transposon system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BODEA, Gabriela O. et al.，Open Biology，2018年07月18日，Vol. 8，No. 7，pp. 1-17

Also Published As

Publication number Publication date
CA3109953A1 (en) 2020-03-05
US20200109398A1 (en) 2020-04-09
JP2025063317A (ja) 2025-04-15
WO2020047124A1 (en) 2020-03-05
US12398392B2 (en) 2025-08-26
AU2019327449B2 (en) 2026-04-09
US20240318170A1 (en) 2024-09-26
CN113286880A (zh) 2021-08-20
BR112021003380A2 (pt) 2021-05-18
US12031129B2 (en) 2024-07-09
US20260185085A1 (en) 2026-07-02
EP3844272A1 (en) 2021-07-07
AU2026205449A1 (en) 2026-07-30
JP2021534798A (ja) 2021-12-16
AU2019327449A1 (en) 2021-03-11
IL280947A (en) 2021-04-29
KR20210049859A (ko) 2021-05-06

Similar Documents

Publication Publication Date Title
JP2025063317A (ja) ゲノムを調節するための方法及び組成物
US11149259B2 (en) CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes
JP2022127638A (ja) 最適化機能ＣＲＩＳＰＲ－Ｃａｓ系による配列操作のための系、方法および組成物
JP7275043B2 (ja) 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法
JP2022546592A (ja) ゲノム組込みのための方法および組成物
JP2017527256A (ja) ＨＢＶ及びウイルス性疾患及び障害のためのＣＲＩＳＰＲ−Ｃａｓ系及び組成物の送達、使用及び治療適用
CN106103705A (zh) 核苷酸重复障碍中crispr‑cas系统的组合物和使用方法
KR20230158531A (ko) 신규 crispr 효소, 방법, 시스템 및 그 용도
EP4337268A1 (en) Methods and compositions for genomic integration
JP2024540390A (ja) 可動因子及びそのキメラ構築物
KR20240116827A (ko) 신규한 crispr 효소, 방법, 시스템 및 이의 용도
JP2025537169A (ja) リコンビナーゼ融合体
WO2023220649A2 (en) Effector protein compositions and methods of use thereof
CN117836009A (zh) 用于基因组整合的方法和组合物
HK40060122A (en) Methods and compositions for modulating a genome
WO2025039972A9 (en) Tls-based gene editing systems
TW202442244A (zh) 用於基因組調節之方法及組合物的Ｐｏｌｙ（Ａ）尾序列
WO2025132755A1 (en) Compositions and methods for delivering transgenes
TW202442245A (zh) 用於基因組調節之方法及組合物的非轉譯區序列及Poly(A)尾序列
WO2024254519A2 (en) Compositions and methods for the modification of human genes expressed by liver cells
WO2025054409A1 (en) Mutant tcbuster transposase with improved solubility
CN120225674A (zh) 雷特综合征疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250411

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250508

R150 Certificate of patent or registration of utility model

Ref document number: 7680351

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150